174 related articles for article (PubMed ID: 28253828)
21. AKT as a therapeutic target in multiple myeloma.
Keane NA; Glavey SV; Krawczyk J; O'Dwyer M
Expert Opin Ther Targets; 2014 Aug; 18(8):897-915. PubMed ID: 24905897
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
[TBL] [Abstract][Full Text] [Related]
23. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
24. Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.
Garcia G; Odaimi M
J Gastrointest Cancer; 2017 Jun; 48(2):121-128. PubMed ID: 28303435
[TBL] [Abstract][Full Text] [Related]
25. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
26. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
27. Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer.
Dent P
Expert Opin Investig Drugs; 2019 Dec; 28(12):1095-1100. PubMed ID: 31783714
[No Abstract] [Full Text] [Related]
28. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.
Diaz-Padilla I; Duran I; Clarke BA; Oza AM
Cancer Treat Rev; 2012 Oct; 38(6):767-75. PubMed ID: 22381585
[TBL] [Abstract][Full Text] [Related]
29. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
30. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
31. Emerging cell-cycle inhibitors for pancreatic cancer therapy.
Bayraktar S; Rocha Lima CM
Expert Opin Emerg Drugs; 2012 Dec; 17(4):571-82. PubMed ID: 23126234
[TBL] [Abstract][Full Text] [Related]
32. Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells.
Ryu YL; Jung KH; Son MK; Yan HH; Kim SJ; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Oct; 353(1):68-77. PubMed ID: 25016056
[TBL] [Abstract][Full Text] [Related]
33. Targeting drivers of melanoma with synthetic small molecules and phytochemicals.
Strickland LR; Pal HC; Elmets CA; Afaq F
Cancer Lett; 2015 Apr; 359(1):20-35. PubMed ID: 25597784
[TBL] [Abstract][Full Text] [Related]
34. [Adjuvant Chemotherapy after Surgery for Pancreatic Cancer].
Furuse J
Gan To Kagaku Ryoho; 2016 Feb; 43(2):160-4. PubMed ID: 27067680
[TBL] [Abstract][Full Text] [Related]
35. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
[TBL] [Abstract][Full Text] [Related]
36. Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.
Zhao C; Xiao H; Wu X; Li C; Liang G; Yang S; Lin J
Oncotarget; 2015 Jun; 6(16):14472-87. PubMed ID: 25961376
[TBL] [Abstract][Full Text] [Related]
37. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Ischenko I; Petrenko O; Hayman MJ
Oncotarget; 2015 Jun; 6(18):15814-27. PubMed ID: 26158412
[TBL] [Abstract][Full Text] [Related]
38. Targeting PI3 kinase in cancer.
Bauer TM; Patel MR; Infante JR
Pharmacol Ther; 2015 Feb; 146():53-60. PubMed ID: 25240910
[TBL] [Abstract][Full Text] [Related]
39. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.
Neuzillet C; Hammel P; Tijeras-Raballand A; Couvelard A; Raymond E
Cancer Metastasis Rev; 2013 Jun; 32(1-2):147-62. PubMed ID: 23085856
[TBL] [Abstract][Full Text] [Related]
40. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]